Impact BioMedical Past Earnings Performance
Past criteria checks 0/6
Impact BioMedical's earnings have been declining at an average annual rate of -48.1%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been declining at an average rate of 14.3% per year.
Key information
-48.1%
Earnings growth rate
-59.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -14.3% |
| Return on equity | -16.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Impact BioMedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 2 | 1 |
| 31 Mar 24 | 0 | -5 | 2 | 1 |
| 31 Dec 23 | 0 | -4 | 2 | 1 |
| 30 Sep 23 | 0 | -6 | 2 | 1 |
| 30 Jun 23 | 0 | -8 | 1 | 1 |
| 31 Mar 23 | 0 | -7 | 1 | 1 |
| 31 Dec 22 | 0 | -7 | 1 | 1 |
| 30 Sep 22 | 0 | -3 | 1 | 1 |
| 30 Jun 22 | 0 | -2 | 1 | 1 |
| 31 Mar 22 | 0 | -1 | 1 | 1 |
| 31 Dec 21 | 0 | -1 | 1 | 1 |
| 30 Sep 21 | 0 | -2 | 1 | 1 |
| 30 Jun 21 | 0 | -1 | 1 | 1 |
| 31 Mar 21 | 0 | -1 | 1 | 1 |
| 31 Dec 20 | 0 | -1 | 0 | 1 |
| 30 Sep 20 | 0 | -1 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Quality Earnings: IBO is currently unprofitable.
Growing Profit Margin: IBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBO is unprofitable, and losses have increased over the past 5 years at a rate of 48.1% per year.
Accelerating Growth: Unable to compare IBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).
Return on Equity
High ROE: IBO has a negative Return on Equity (-16.37%), as it is currently unprofitable.